Fortrea Holdings Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fortrea Holdings Inc (FTRE) reports solid Q2 performance and focuses on margin improvement and growth opportunities

Fortrea Holdings Inc (FTRE) delivered a solid quarter with a strategic focus on margin improvement, cost reductions, and innovative offerings despite challenges in biotech predictions.
The company's strengths in diversified portfolio, value proposition, and customer-centric approach position it well for future growth and financial performance enhancements.
While facing challenges in book-to-bill ratio and future accruals, Fortrea Holdings is actively addressing these issues through restructuring and efficiency initiatives.
Opportunities in margin improvement, AI tools utilization, and potential Q4 activity in large pharma offer avenues for growth and enhanced financial performance in the coming quarters.

Fortrea Holdings Inc (FTRE) reports solid Q3 performance and addresses growth challenges

Fortrea Holdings Inc (FTRE) showcased resilience and success in large pharma and biotech projects, despite revenue decline.
The company's focus on cost reductions, cash flow generation, and transitioning from their parent company reflects strategic adaptability.
Challenges in revenue decline, margin improvement, and project mix management are being addressed to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.

Industry veteran brings more than three decades of experience spanning R&D, commercialization, and market access Industry veteran brings more than three decades of experience spanning R&D, commercialization, and market access

Fortrea Appoints Life Science Executive Dr. John Doyle to Lead Consulting Team

DURHAM, N.C., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its third quarter 2023 financial results before the market opens on Monday, November 13, 2023. Fortrea will host a conference call at 9:00 am ET that day to review its third quarter performance and conduct a question-and-answer session.

Fortrea Announces Date for Third Quarter 2023 Financial Results and Conference Call

DURHAM, N.C., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that its Global Chief Information Security Officer (CISO), Jim Cameli, has been named to HotTopics' Global CISO 100 2023.

Fortrea's Jim Cameli Named a Top 100 Global Chief Information Security Officer by HotTopics

Cricut

Intrepid Potash

The recent surge in analyst coverage for stocks such as Intrepid Potash (IPI), Fortrea (FTRE) and Cricut (CRCT) indicates the potential for significant price appreciation in the near term.

New Analysts Initiate Coverage: 3 Stocks to Watch

DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will participate in a fireside chat at the Baird Global Healthcare Conference on Tuesday, September 12, at 10:15 am ET.

Fortrea to Present at the Baird 2023 Global Healthcare Conference

DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13 at 9:30 am ET.

Fortrea to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Fortrea Holdings, a spin-off from LabCorp, has seen a substantial decline in its share price since its July spin-off. The company has outlined a not-so-impressive outlook for the year, with flat earnings expected and a high leverage multiple. Given this situation, it is hard to see appeal emerging here, as some execution is needed before I am considering a potential.

Fortrea Holdings: Many Questions Post The Spin-Off

Fortrea Holdings Inc. (NASDAQ:FTRE ) Q2 2023 Earnings Call Transcript August 14, 2023 8:00 AM ET Company Participants Hima Inguva - Head of IR Tom Pike - President & CEO Jill McConnell - CFO Mark Morais - COO Conference Call Participants David Windley - Jefferies Elizabeth Anderson - Evercore Casey Woodring - JPMorgan Max Smock - William Blair Sandy Draper - Guggenheim Derik De Bruin - Bank of America Operator Good morning, and thank you for standing by. Welcome to the Fortrea Second Quarter 2023 Earnings Conference Call.

Fortrea Holdings Inc. (FTRE) Q2 2023 Earnings Call Transcript

Fortrea Holdings Inc. ( FTRE , Financial) is a leading provider of comprehensive phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services. The company partners with emerging and large biopharma, medical device and diagnostic companies to drive health care innovation and improve the lives of patients worldwide.

Fortrea: The Main Hurdle to Focus on Now Is Growth

Fortrea's Q2 revenue was flat year over year, and its earnings declined. The company's full-year outlook pointed to more of the same for the rest of 2023.

Why Fortrea Holdings Stock Is Sinking Today

DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today reported financial results for the second quarter ended June 30, 2023.

Fortrea Reports Second Quarter 2023 Results and Provides Full-Year 2023 Guidance

DURHAM, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2023 financial results before the market opens on Monday, August 14, 2023. Fortrea will host a conference call at 8:00 am ET that day to review its second quarter performance and conduct a question-and-answer session.

Fortrea Announces Date for Second Quarter 2023 Financial Results and Conference Call

Fortrea was spun off from Labcorp on July 3. I am rating the new company as a strong hold based upon its long history of financial success, its strong position in a growing industry, its extensive capabilities, and valuation. I am waiting for formal financial projections before adding more shares.

Fortrea: A Strong Hold Following The Spin-Off

Labcorp Holdings Inc

Company completes spin-off from Labcorp and begins trading on Nasdaq under ticker “FTRE” Independent company positioned to capitalize on growth opportunities in phases I-IV clinical trials and patient access, and to extend leading positions in oncology, clinical pharmacology and partnership models DURHAM, N.C., July 03, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has successfully completed its previously announced spin-off from Labcorp (NYSE: LH).

Fortrea Launches as Leading, Global Contract Research Organization Positioned to Bring Life-Changing Therapies to Patients Faster

News for Fortrea Holdings Inc Stock (FTRE)